In yesterday’s Wall Street session, Bristol-Myers Squibb Co. (NYSE:BMY) shares traded at $51.25, up 0.45% from the previous session.
As we calculate the median target price by taking the range between a high of $90.00 and a low of $50.00, we find $68.00. Given the previous closing price of $51.02, this indicates a potential upside of 33.28 percent. BMY stock price is now -12.59% away from the 50-day moving average and -21.22% away from the 200-day moving average. The market capitalization of the company currently stands at $104.28B.
Brokers who have rated the stock have averaged $66.19 as their price target over the next twelve months.
With the price target reduced from $55 to $53, HSBC Securities Upgraded its rating from Reduce to Hold for Bristol-Myers Squibb Co. (NYSE: BMY).
In other news, Powell Ann, EVP, Chief Human Resources sold 17,986 shares of the company’s stock on Aug 24. The stock was sold for $1,101,642 at an average price of $61.25. Upon completion of the transaction, the EVP, Chief Human Resources now directly owns 27,868 shares in the company, valued at $1.43 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 03, EVP, Chief Research Officer Plenge Robert M sold 732 shares of the business’s stock. A total of $44,754 was realized by selling the stock at an average price of $61.14. This leaves the insider owning 6,584 shares of the company worth $0.34 million. Insiders disposed of 747,378 shares of company stock worth roughly $38.3 million over the past 1 year. A total of 0.14% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BMY stock. A new stake in Bristol-Myers Squibb Co. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $98,700,000. LAURION CAPITAL MANAGEMENT LP invested $43,027,000 in shares of BMY during the first quarter. In the first quarter, UNISUPER MANAGEMENT PTY LTD acquired a new stake in Bristol-Myers Squibb Co. valued at approximately $21,849,000. ARMISTICE CAPITAL, LLC acquired a new stake in BMY for approximately $20,408,000. TREXQUANT INVESTMENT LP purchased a new stake in BMY valued at around $19,251,000 in the second quarter. In total, there are 3,229 active investors with 79.67% ownership of the company’s stock.
Monday morning saw Bristol-Myers Squibb Co. (NYSE: BMY) opened at $51.73. During the past 12 months, Bristol-Myers Squibb Co. has had a low of $49.49 and a high of $81.43. As of last week, the company has a debt-to-equity ratio of 1.35, a current ratio of 1.18, and a quick ratio of 1.07. According to the stock market information, the enterprise value for the company is $135.86B, which is based on a 13.00 price-to-earnings ratio, a 15.60 price-to-earnings-growth ratio, and a beta of 0.38. The fifty day moving average price for BMY is $58.42 and a two-hundred day moving average price translates $64.95 for the stock.
The latest earnings results from Bristol-Myers Squibb Co. (NYSE: BMY) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.75, missing analysts’ expectations of $1.98 by -0.23. This compares to $0.75 EPS in the same period last year. The net profit margin was 18.44% and return on equity was 26.87% for BMY. The company reported revenue of $10.97 billion for the quarter, compared to $11.22 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.25 percent. For the current quarter, analysts expect BMY to generate $10.97B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 08/01/2023. Investors who held shares on 07/07/2023 were paid a $0.57 dividend. On an annualized basis, this represents a $2.23 dividend and a 4.36% percent yield. There was an ex-dividend date of 07/06/2023 for this dividend. In terms of dividend payout ratio, BMY is presently at 74.28%.
Bristol-Myers Squibb Co.(BMY) Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
